9 articles found
Flow Neuroscience's transcranial direct current stimulation device becomes first prescription brain stimulation therapy available for home use, offering new option for treatment-resistant depression
Federal initiative targets individuals experiencing homelessness and substance use disorders through outcomes-based approach, but faith-based inclusion and punitive policy context raise concerns among public health advocates.
Ann Arbor-based online addiction provider now treats kratom and 7-hydroxymitragynine dependence through app-based platform, addressing regulatory gap as FDA restricts potent derivatives but leaf products remain unregulated nationwide.
American Society of Addiction Medicine releases first comprehensive update to youth substance use disorder treatment standards in over a decade, addressing telehealth, trauma-informed care, and medication access.
Workit Health's evidence-based virtual care model delivers 62% rural retention at three months—more than double competing programs—with peer-reviewed studies in JAMA Network Open showing perfect buprenorphine adherence among participants.
JAMA Network Open study analyzing Medicare records shows specialists using telemedicine heavily saw only 0.9% more rural patients while treating 3.6% fewer new patients overall.
DEA and HHS codify pandemic-era flexibility, allowing providers to initiate and maintain buprenorphine treatment entirely via telehealth through the end of 2026, a move experts say could save lives and reshape addiction care nationwide.
Digital therapeutics for substance use disorders are gaining traction as researchers identify key strategies to improve engagement and outcomes, with apps reaching patients beyond traditional clinic walls.
New federal rules allow providers to prescribe six-month supply of buprenorphine via audio-only telehealth for opioid use disorder treatment, eliminating pandemic-era restrictions while implementing safeguards.